Participant assessment | Who | When | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Usual care team | Consultant | Research nurse | Participant | Research team | Pre-screening | Cohort baseline appointment | Surgery | Cohort follow-up/true trial baseline appointment | 6-month intervention duration | 3-month follow-up appointment | 6-month follow-up appointment | Evaluation interview | |
Eligibility screening | X | X | X | Â | Â | X | Â | Â | Â | Â | Â | Â | Â |
Informed consent | Â | Â | X | X | Â | Â | X | Â | X | Â | Â | Â | Â |
Demographic data | Â | Â | Â | X | Â | Â | X | Â | X | Â | X | X | Â |
Family medical history | Â | Â | Â | X | Â | Â | X | Â | X | Â | X | X | Â |
Anthropometric data weight, height, % body fat | Â | Â | X | Â | Â | Â | X | Â | X | Â | X | X | Â |
Blood sample | Â | Â | X | Â | Â | Â | X | Â | X | Â | Â | X | Â |
Diet data FFQ [43] | Â | Â | Â | X | Â | Â | X | Â | X | Â | X | X | Â |
Physical activity data Recent Physical Activity Questionnaire [44] | Â | Â | Â | X | Â | Â | X | Â | X | Â | X | X | Â |
Urinary symptoms ICSmale-SF [45] | Â | Â | Â | X | Â | Â | X | Â | X | Â | X | X | Â |
Psychological measures POMS-SF [46] and Benefit Finding Scale [47] | Â | Â | Â | X | Â | Â | X | Â | X | Â | X | X | Â |
 |  |  | X |  |  | X |  | X |  | X | X |  | |
Quality of life measures FACT-P [48] | Â | Â | Â | X | Â | Â | X | Â | X | Â | X | X | Â |
General health data SF-12 [49] | Â | Â | Â | X | Â | Â | X | Â | X | Â | X | X | Â |
Cancer related fatigue FACIT-Fatigue [48] | Â | Â | Â | X | Â | Â | X | Â | X | Â | X | X | Â |
Lifestyle data Drinking and smoking | Â | Â | Â | X | Â | Â | X | Â | X | Â | X | X | Â |
Accelerometry data | Â | Â | Â | X | Â | Â | X | Â | X | Â | Â | X | Â |
Prostate tissue | Â | X | Â | Â | Â | Â | Â | X | Â | Â | Â | Â | Â |
Pedometer data | Â | Â | Â | X | Â | Â | Â | Â | Â | X | Â | Â | Â |
Daily monitoring data Step count, record of fruit, vegetable, dairy and lycopene intake | Â | Â | Â | X | Â | Â | Â | Â | Â | X | Â | Â | Â |
Qualitative evaluation data | Â | Â | Â | X | X | Â | Â | Â | Â | Â | Â | Â | X |